March 18, 2018
US National Lung Screening Trial PI visits Optellum
Optellum is delighted to welcome Dr. Christine Berg, the co-Principal Investigator of the US National Lung Screening Trial (NLST), the biggest ever randomized clinical study, to learn more about Optellum and our work to redefine early interception of lung cancer with AI.
Recent posts
August 24, 2026 / News & Press, Partnerships
SimonMed Launches World’s First Seamlessly Integrated AI Lung Nodule Risk Assessment WorkflowSimonMed is creating the first fully automated AI-powered lung cancer risk assessment workflow deployed at enterprise scale, combining multiple FDA-cleared AI technologies into a...
Read more
August 13, 2026 / News & Press, Partnerships
Coreline Soft and Optellum announce intent to collaborate to advance AI...Proposed collaboration would make Coreline Soft's FDA-cleared lung nodule detection capability available through Optellum's LungOS® platform
Read more
June 15, 2026 / News & Press, Partnerships
Optellum Awarded NIHR Funding for Multi-Site NHS Pilot Study for Accelerated...Optellum announced it has been awarded funding for a competitive programme, Invention for Innovation (i4i), focused on transformative and disruptive innovations to reduce waiting...
Read more
Optellum is trusted by industry & academic leaders
Certification
Redefining early intervention of lung disease
starting with one of the deadliest, lung cancer
Contact us